+ T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined. 
Higher current CD4
+ T-cell counts in patients on firstline highly active antiretroviral therapy (HAART) are associated with lower rates of non-AIDS-related diseases and AIDS, even when only the patients who attain undetectable levels of HIV RNA are considered [1] . Six months after starting HAART, current (but not baseline) CD4 + T-cell counts and viral loads closely correlate with subsequent disease progression [2] ; thus, a greater increase in CD4 + T-cell count after the first months of HAART might have a beneficial effect on prognosis.
The increase in CD4 + T-cell count after the start of HAART characteristically has a biphasic pattern. There is a steep initial phase, which probably reflects a redistribution of T-cells mediated by the resolution of the immune activation sequestering T-cells within lymphoid tissues [3] [4] [5] . This is followed by a second phase
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Predicting the magnitude of short-term CD4 + T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy Introduction during which CD4 + T-cells can continue to increase, albeit at a slower rate in patients who maintain viral loads of <1,000 copies/ml [6] [7] [8] , or plateau after a variable number of years [9] [10] [11] .
No data are available concerning average CD4 + T-cell recovery in the initial treatment phase of patients both tolerating their first HAART and attaining an optimal virological response. In particular, the range of CD4 + T-cell recovery is very wide in patients in whom viral replication is optimally controlled (that is, HIV RNA values are <50 copies/ml). Knowing at the time of starting HAART which patients are at risk of a lower 6 month increase in CD4 + T-cell count, despite a successful virological response, will help the design of more appropriate therapeutic strategies. Furthermore, it has been observed that HCV viraemic patients tend to be less likely to achieve an increase of >100 CD4 + T-cells/µl, thus suggesting that HCV viraemia plays a direct role in the CD4 + T-cell count response to HAART [12] .
The aim of this study was to characterize the increase in CD4
+ T-cell counts in a large multicentre cohort of HAART-naive, HIV-infected patients who achieved full viral suppression after 24 weeks of treatment with first-line HAART. We also assessed the factors predicting short-term CD4 + T-cell recovery, giving particular attention to the role of HCV coinfection.
Methods
This retrospective observational multicohort study enrolled HIV-infected patients from four leading cohorts starting their first-line HAART regimen and who met the necessary criteria: documented HIV infection; first HAART regimen started between January 1996 and September 2006, and continued for 6 months without any change; at least two determinations (baseline and week 24) of CD4 + T-cell count and percentage (CD4 + %) and HIV RNA values assessed on the same day at all of the considered time points of follow-up; HIV RNA values of <50 copies/ml at month 6; and known HCV coinfection status. The baseline values were those recorded nearest to the start of HAART during the 90 days preceding initiation. The 3 month values ranged from 60 to 120 days from the start of the first HAART; the value closest to 90 days was chosen in the case of patients with more than one value available in this time window. The 6 month values ranged from 150 to 210 days from the start of the first HAART; the value closest to 180 days was chosen in the case of patients with more than one value available in this time window. CD4 + T-cell recovery was calculated as the change in CD4 + T-cell count from baseline and was evaluated at week 12 and week 24. The reasons for discontinuation of first HAART could not be analysed, because these data were not consistently collected within each cohort during the time period considered in this study.
Statistical analysis
The continuous variables were described by means of median values and quartiles (Q1-Q3). Baseline CD4 + % values were stratified by quartiles (≤8.7%, 8.8-14.7%, 14.8-21.2% and >21.2%), as were the baseline CD4 + T-cell counts (≤99, 100-226, 227-332 and >332 cells/ µl) and baseline HIV RNA values, which were also log 10 transformed (≤4.38, 4.39-4.91, 4.92-5.34 and >5.34 log 10 copies/ml). The immunological and virological quartiles were also estimated in the subgroup of patients with available data at week 12: as no different values were found, the same quartiles were used in the 12-week and 24-week analyses.
Baseline patient characteristics were described for the overall sample and according to HCV coinfection status and type of first-line HAART. One-way ANOVA or the Student's t-test was used to compare the continuous variables and the χ 2 test was used to study the associations between categorical variables. The McNemar test was used to evaluate changes from baseline in proportions.
The change in CD4 + T-cell count was estimated and described in relation to the strata of baseline CD4 + T-cell counts, baseline CD4 + % and baseline HIV RNA load; further stratification variables included gender, HIV risk group, type of first-line HAART, HCV coinfection, the presence of hepatitis B surface antigen and previous AIDS-defining events.
As multiple examinations were available for most patients, mixed linear univariable and multivariable with fixed effects were fitted to estimate the independent contribution of the baseline factors in predicting the 12-and 24-week change in CD4 + T-cell counts. The covariates included in the multivariable models were chosen by considering the factors that had a relevant effect on outcomes (univariable analysis) and other potential confounders, excluding those factors with similar clinical meaning and/or highly correlated to other covariates. Adjusted mean values and the corresponding standard errors were calculated. Statistical significance of the overall effect was calculated and reported for all the considered variables; in addition, post-hoc t-tests were calculated among the adjusted means of the significant variables taking into account Bonferroni's correction.
All of the statistical tests were two-sided at the 5% level and were made using SAS Software (release 9.1; SAS Institute, Cary, NC, USA).
Results
A total of 1,488 patients fulfilled all of the inclusion criteria and were considered in the analysis; the baseline characteristics of the overall sample are shown in Table 1 (412 patients), lopinavir/ritonavir (267 patients), tenofovir (278 patients), stavudine (284 patients), didanosine (279 patients), indinavir (237 patients), nelfinavir (161 patients) or nevirapine (151 patients). Table 2 reports the baseline demographic and clinical characteristics of the patients according to the type of therapy. Injection drug users (IDU) were less likely to start a protease inhibitor based regimen boosted with ritonavir (PI/r) if they were coinfected with HCV; in fact, among the 310 IDU patients with HCV coinfection, 10 (3.2%) patients started a nucleoside reverse transcriptase inhibitor (NRTI)-based regimen, 148 (47.7%) an unboosted PI regimen, 103 (33.2%) a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen and 49 (15.8%) a PI/r-based regimen. Among the 963 patients with other risk factors and HCV coinfection the distribution was as follows: 1 (1.1%) patient started an NRTI-based regimen, 40 Tables 3 and 4 show the unadjusted (univariable analysis) and adjusted (multivariable analysis) means of the 12-and 24-week change in CD4 + T-cell counts from baseline in relation to the demographic and clinical characteristics. At univariable analysis, at both week 12 and 24, the crude increase in CD4 + T-cell counts was significantly greater among older patients (P<0.0001) and among patients with higher baseline CD4 + T-cell counts (overall effect: P<0.0001), in patients with higher baseline CD4 + % (overall effect: P<0.0001), higher baseline CD4 + /CD8 + (overall effect: P=0.001) and higher baseline log 10 HIV RNA values (overall effect: P<0.0001). Increases were also greater in patients without HCV coinfection than in those with coinfection (P<0.0001), in patients who were not IDUs (P<0.0001), in those treated with a boosted PI-based first-line HAART (overall effect: P<0.0001) and in those who received a thymidine analogue (P<0.0001). Figure 1 shows the crude means of the 12-and 24-week immunological changes according to the HCV coinfection status ( Figure 1A ) and the type of first-line HAART ( Figure 1B) . The joint effect of HCV coinfection status and the type of first-line HAART on CD4 + T-cell recovery was highly significant both at week 12 (P<0.0001) and week 24 (P<0.0001) and is shown in Figure 1C . The adjusted mean (±sem) of the 12-week change in CD4 + T-cell counts from baseline was significantly lower in patients treated with an unboosted PI-based regimen (difference between the adjusted means, boosted PI-based regimen as reference group -58.3 ±7.5; P<0.0001), an NNRTI-based regimen (difference between the adjusted means, boosted PI-based regimen as reference group -26.6 ±7.5; P=0.002) or an NRTI-based regimen (difference between the adjusted means, boosted PI-based regimen as reference group -77.4 ±16.4; P<0.0001) with respect to the boosted PI-based regimen.
The adjusted mean (±sem) of the 24-week change in CD4 + T-cell count from baseline was significantly lower in patients treated with an unboosted PI-based regimen (difference between the adjusted means, boosted PI-based regimen as reference group -60.9 ±6.9; P<0.0001), an NNRTI-based regimen (difference between the adjusted means, boosted PI-based regimen as reference group -20.6 ±7.5; P=0.020) or an NRTI-based regimen (difference between the adjusted means, boosted PI-based regimen as reference group -82.2 ±17.9; P<0.0001) with respect to the boosted PI-based regimen.
The adjusted mean (±sem) of the 24-week changes in CD4 + T-cell count from baseline was significantly higher in patients who received a thymidine analogue (difference between the adjusted means, patients who did receive a thymidine analogue as reference group 51.0 ±4.9; P<0.001), in patients without HCV infection than in those with coinfection (difference between the adjusted means, HCV monoinfection as reference group 17.6 ±6. 4 Figure 2 shows estimates of the adjusted 12-and 24-week mean (±sem) CD4 + T-cell count changes considering the clinical conditions found to be significant determinants of these changes.
Discussion
Any gain in CD4 + T-cell count might be important for the prognosis of HIV-infected patients, because higher current CD4 + T-cell counts are associated with reduced rates of AIDS and death due to any cause [13] .
We found that 24-week CD4 + T-cell recovery was greatest among patients without HCV coinfection, those who started HAART with a higher CD4 + % and higher viral loads and those who received a boosted PI-based first-line regimen. By contrast, CD4 + T-cell recovery was lower in patients coinfected with HCV, those who started HAART with lower CD4 + %, lower viral loads and in patients who did not receive a boosted PI-based first-line regimen. Age and baseline CD4 + T-cell counts had no independent effect on CD4 + T-cell recovery. The correlation between the absolute number of CD4 + T-cells at baseline and the slope of CD4 + T-cell recovery does not seem to be univocal. Hunt et al. [6] found that lower pre-therapy CD4 + T-cell counts were associated with greater CD4 + T-cell gains, particularly during the first 2 years of suppressive HAART. By contrast, higher pre-therapy CD4 + T-cell counts have been found to be independently associated with greater increases in CD4 + T-cell counts in other studies [9, 14] , but other authors have not found any significant association between the two variables [11, [15] [16] [17] [18] .
According to some authors, CD4 + % might be a better predictor of disease progression than absolute numbers, as it has been found to predict disease progression in HIV-infected patients starting HAART with CD4 + T-cell counts of >350 T-cells/µl [19] . Moreover, baseline CD4 + % is associated with AIDS-free survival and has greater prognostic value than baseline CD4 + T-cell counts [20] . It has also been found that values of <15% are independent predictors of mortality in AIDS-free patients starting HAART, including those with CD4 + T-cell counts of between 200 and 350 cells/µl [21] . We did not look at the association between baseline CD4 + % and the risk of death because our follow-up was short, but one original finding of our study was the positive correlation between baseline CD4 + % and the change in CD4 + T-cell count from baseline, although the differences across the baseline CD4 + % quartiles were rather small. Baseline viral load was a strong predictor of the change in CD4 + T-cell count, which is in line with the findings of a number of other studies [16, 22, 23] . In particular, it has been found that higher pre-treatment HIV-1 RNA levels are associated with a steeper initial increase in CD4 + T-cells [5, 15] . This might be due to a reversal in accelerated cell disruption and activation of the immune system, with the consequent redistribution of CD4 + T-cells to the circulation after viral suppression [24] [25] [26] .
Significantly smaller increases in CD4 + T-cell counts have been observed in patients with HCV coinfection during the first year of therapy [16, 27, 28] . It has been hypothesized that HCV viraemia has a direct role in + /CD8 + ratio and calendar year of highly active antiretroviral therapy start) were considered at their mean values. Categorical variables included the categories shown in Table 3 . NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted PI.
the CD4
+ T-cell count response to HAART, because a large prospective study of Italian HIV-infected patients found that the likelihood of achieving an increase in CD4 + T-cell count of >100 cells/µl was 18% less for HCV viraemic than in patients with no coinfection [12] . Although the reasons for this difference are largely unknown, CD4 + T-cell depletion has been independently associated with the severity of liver fibrosis in patients with HCV-HIV coinfection [29] . In addition, it has been found that the risk of death due to liver disease is greater in patients with lower current CD4 + T-cell counts [30] ; however, no evidence for a residual effect of HCV on CD4 + T-cell response was found in a study of patients with a suppressed viral load [31] . The results of our study confirm that immune recovery is impaired in patients with HCV coinfection; therefore, such patients should be treated with regimens that are most effective in attaining the greatest increase in CD4 + T-cell count. We found that the use of boosted PI-based regimens favours CD4 + T-cell recovery. This finding is consistent with those of the randomized ACTG 5142 clinical trial [32] in which treatment-naive patients receiving a regimen based on lopinavir/ritonavir showed greater increases in CD4 + T-cell count than those treated with efavirenz-based therapy, despite their worse virological response. Our observation is also in line with the results of the EuroSIDA cohort [33] . With respect to treatment with NNRTIs, increased CD4 + T-cell counts might result from reduced CD4 + T-cell apoptosis, which has been observed during treatment with PIs regardless of the reduction in viral load [34, 35] . The improved results seen for boosted PIs with respect to unboosted PIs is probably due to the better viro-immunological activity of boosted PIs [36] . Other authors did not find such an association with this type of first-line HAART [37] ; this discrepancy could be due to the different study design, the different follow-up, the inclusion of non-responders in the analysis and the more frequent use of unboosted PIs among the studied patients.
We found that patients receiving thymidine analogues had better immune recovery; this is in apparent contrast with previous studies showing that those randomized to tenofovir/emtricitabine plus efavirenz or abacavir/ lamivudine plus efavirenz had small, but significantly higher, CD4 + T-cell gains than those randomized to zidovudine/lamivudine plus efavirenz [38, 39] . However, our findings might be explained by differences and high heterogeneity in the regimens used: many of the patients not treated with thymidine analogues did not receive tenofovir or abacavir, but instead received didanosine, many of those treated with thymidine analogues received stavudine rather than zidovudine and the third drug of the regimen was often a PI (with or without boosting) rather than efavirenz.
A younger age has been associated with better CD4 + T-cell recovery [9, 16, 23] but, as we did not find such a correlation over 24 weeks, we hypothesize that age influences the second phase of immune recovery more than the early phase.
Our study has the limitations common to all retrospective studies. The inclusion of patients who were unlikely to discontinue their first regimen and with known HCV antibody test results prevent us from extending the validity of our results to all patients starting first-line HAART. Furthermore, our results might be limited by a possible effect of baseline CD4 + T-cell counts on CD4 + T-cell recovery and we cannot exclude the possibility that the upward trend in CD4 + T-cell counts might have been partially due to the well-known statistical artefact of a regression to the mean. In any case, as no duplicate of the baseline CD4 + T-cell recordings was available to allow us to determine and subsequently adjust for the effect of regression to the mean, the changes must be interpreted cautiously [40] . In addition, patients were not randomly allocated to the type of antiretroviral treatment and, although confounding cannot be excluded, patients were well balanced among the four groups of HAART, suggesting that no major selection bias can be hypothesized.
Our study has some distinctive characteristics that provide unique information. Firstly, it included only patients who did not change their first-line regimen and showed an optimal virological response. This allowed us to analyse the influence of HCV coinfection and different types of regimen on CD4 + T-cell recovery and to avoid the effects induced by changes in HAART and the effects of a virological response on immunological changes. Secondly, the analysis included a large number of women and patients with HCV coinfection.
In conclusion, 6-month CD4 + T-cell recovery is a complex phenomenon that arises from the interplay of a number of concomitant factors. Clinicians need to be aware that T-cell recovery might vary widely depending on baseline characteristics, even among patients with undetectable viraemia 6 months after starting their first regimen. Careful evaluation of all of the variables capable of influencing this recovery might help in offering patients not only viral undetectability, but also the best possible immune recovery. Among antiretroviral therapy (ART)-naive HIV-infected patients who tolerate their first-line HAART and show an optimal virological response after 6 months, 24-week CD4 + T-cell recovery is significantly greater in those without HCV coinfection, in those with a high viral load and high CD4 + percentages, and in those treated with a boosted PI-based regimen. This information might be helpful in making clinical decisions in ART-naive HIV-infected patients intending to start first-line HAART.
